Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Business
STAT+

5 things to know about Sage’s must-win drug trials in postpartum depression

  • Adam Feuerstein

By Adam Feuerstein Sept. 13, 2017

Reprints
Neurons
APStock

It’s do-or-die time for Sage Therapeutics (SAGE).

The failure of the brexanolone phase 3 clinical trial in severe epilepsy announced Tuesday bent, but did not break, Sage’s stock price. The company is getting a second chance to prove the therapeutic value of brexanolone with two phase 3 studies in women with postpartum depression.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Top FDA official: Agency needs to start using accelerated…
Top FDA official: Agency needs to start using accelerated approval for gene therapies
Watch: P-value, an important measurement in clinical trials, explained
Watch: P-value, an important measurement in clinical trials, explained
Vote now in STAT Madness 2023
Vote now in STAT Madness 2023
Senator calls for probe of conflict of interest on…
Senator calls for probe of conflict of interest on federal panel overseeing dietary guidelines
Top FDA official: Agency needs to start using accelerated…
Top FDA official: Agency needs to start using accelerated approval for gene therapies
Pharmalittle: Manufacturers say bird flu shots for humans can…
Pharmalittle: Manufacturers say bird flu shots for humans can be made quickly; obesity guidelines for children…

Recommended Stories